U.S. federal trademark · Serial No. 99333233 · Reg. No. 8161176
Pharmaceuticals namely plasma derived and recombinant immunoglobulins for use in the treatment of infectious diseases including CMV disease, Hepatitis B, Varicella Zoster, and rabies, Hematologic conditions including Idiopathic Thrombocytopenic Purpura (ITP). Respiratory conditions including Alpha-1 Antitrypsin Deficiency, Obstetrics and Gynecology (OBGYN) conditions such as hemolytic disease of the newborn, Transplantation treatments including solid-organ transplants and hematopoietic stem-cell transplantation (HSCT); pharmaceuticals namely plasma derived and recombinant proteins for treating pulmonary diseases, congenital Alpha-1 Antitrypsin deficiency, post-exposure prophylaxis against viral infection, preventing and treating immune tolerance based diseases, treating immunological disorders and treating inflammatory diseases; pharmaceuticals namely coagulation factors for bleeding disorders; plasma-derived protein preparations for therapeutic use; vaccines; pharmaceutical preparations for the treatment of lung diseases; pharmaceutical preparations for the treatment or prevention of thrombo-embolic disorders; pharmaceutical preparations for anesthesia analgesia for surgery; pharmaceutical preparations for treatment of CMV infection and disease; pharmaceutical preparations for the treatment of Varicella Zoster Virus; pharmaceutical preparations for treatment of Hepatitis; pharmaceutical preparations for the treatment of Rabies.
Source: USPTO federal trademark records. Informational only, not legal advice. Status and details may lag the live USPTO database.